Related Experiment Video

Updated: Jun 4, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Protein phosphatase 2A as a potential target for anticancer therapy

Peter Kalev1, Anna A Sablina

  • 1Center for Human Genetics, KULeuven, Belgium.

Anti-Cancer Agents in Medicinal Chemistry
|February 4, 2011
PubMed

Insights

Targeting protein phosphatase 2A (PP2A) shows potent anti-tumor activity. Modulating PP2A offers a promising new strategy for effective cancer treatment, distinct from current kinase inhibitor therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Kinase oncogenes are established cancer drivers with approved targeted therapies.
  • The role of protein phosphatases in cancer, particularly protein phosphatase 2A (PP2A), is less understood.
  • PP2A is a serine-threonine phosphatase involved in regulating critical signaling pathways and may act as a tumor suppressor.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting protein phosphatase 2A (PP2A) in cancer treatment.
  • To explore PP2A as a novel anti-cancer target, contrasting with existing kinase inhibitor strategies.

Main Methods:

  • Review of existing literature on kinase oncogenes and protein phosphatases in cancer.
  • Analysis of recent studies demonstrating pharmacological modulation of PP2A activity.
  • Evaluation of in vitro and in vivo cancer models assessing PP2A's anti-tumor effects.

Main Results:

  • Pharmacological modulation of PP2A activity has demonstrated potent anti-tumor effects.
  • These effects were observed in both in vitro and in vivo cancer models.
  • PP2A's role as a potential tumor suppressor is supported by its involvement in key signaling pathways.

Conclusions:

  • Protein phosphatase 2A (PP2A) represents a promising therapeutic target for cancer treatment.
  • Targeting PP2A offers a novel approach to cancer therapy, complementing existing kinase inhibitor strategies.
  • Further research into PP2A modulation could lead to new effective anti-cancer therapies.

More Related Videos

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors10:17

A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors

Published on: April 29, 2022

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...